BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On April 6, 2017, Biostage, Inc., or the Company, presented a
poster presentation relating to preclinical data of its Cellspan
Esophageal Implant at the Society for Biomaterials 2017 Annual
Meeting and Exposition, being held April 5, 2017 through April 8,
2017 in Minneapolis, Minnesota. The Company hereby furnishes the
poster presentation as Exhibit 99.1 to this Current Report on
Form 8-K.
Also on April 6, 2017, the Company issued a press release
announcing the poster presentation at the Society for
Biomaterials meeting. A copy of the press release is furnished
herewith as Exhibit 99.2 to this Current Report on Form 8-K.
The information furnished to Item 7.01, including Exhibits 99.1
and 99.2, shall not be deemed filed for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act) and will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except to the extent that the
Company specifically incorporates it by reference.
The information furnished in this report, including Exhibits 99.1
and 99.2, shall not be deemed to constitute an admission that
such information or exhibit is required to be furnished to
Regulation FD or that such information or exhibit contains
material information that is not otherwise publicly available. In
addition, the Company does not assume any obligation to update
such information or exhibit in the future.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Title | |
| 99.1 | Poster Presentation of Biostage, Inc. | |
| 99.2 | Press Release issued by Biostage, Inc. on April 6, 2017. |
About BIOSTAGE, INC. (NASDAQ:BSTG)
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world. BIOSTAGE, INC. (NASDAQ:BSTG) Recent Trading Information
BIOSTAGE, INC. (NASDAQ:BSTG) closed its last trading session down -0.004 at 0.324 with 3,443,876 shares trading hands.
